American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

FDA Initiative Targets Preventable Harms From Medications

Agency Seeks Physician Input

By News Staff

The FDA recently launched its Safe Use Initiative, a program intended to reduce the likelihood of preventable harm from OTC and prescription drug use.
Safe Use
The initiative will examine multiple sources of preventable harm, including unintentional misuse of medications, abuse and attempts at self-harm. The agency is seeking input (2-page PDF; About PDFs) from physicians and other stakeholders to identify drugs and classes of drugs linked to such events.

The FDA said it will collaborate with patients, consumers, caregivers, health care professionals, pharmacists, health care systems, insurers, drug manufacturers and other federal agencies to develop a list of specific problems, interventions for reducing harm from those problems and metrics for judging success in meeting the goal of reducing preventable harm.

"Only through coordinated interventions across all sectors of the health care system can we substantially reduce preventable injuries from using medications," said Janet Woodcock, M.D., director of the FDA's Center for Drug Evaluation and Research, in a news release announcing the initiative. "All participants in the health care community have a role to play in reducing the risks and preventing injuries from medication use.”

Woodcock is co-author of a report -- "FDA's Safe Use Initiative - Collaborating to Reduce Preventable Harm from Medicines" -- (28-page PDF; About PDFs) that details the initiative's goals.

In addition, the 2010 Physicians' Desk Reference now available for distribution includes a letter from Woodcock highlighting the Safe Use Initiative and urging physicians to report adverse events to the FDA. A facing page directs physicians to the Health Care Notification Network, an online drug alert service of the newly formed PDR Network that is free to AAFP members.

The Institute of Medicine has estimated that 1.5 million preventable adverse drug events occur each year, at a cost of more than $4 billion. According to the FDA, the amount of preventable harm tied specifically to misuse of OTC medications is unknown.

Share this on AAFP Connection

Health of the Public

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing